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Summary
Low platelet count, or thrombocytopenia, is a common haema-
tological abnormality, with a wide differential diagnosis, which
may represent a clinically significant underlying pathology.
Macrothrombocytopenia, the presence of large platelets in com-
bination with thrombocytopenia, can be acquired or hereditary
and indicative of a complex disorder. In this review, we discuss
the interpretation of platelet count and volume measured by
automated haematology analysers and highlight some impor-
tant technical considerations relevant to the analysis of blood
samples with macrothrombocytopenia. We review how large
cohorts, such as the UK Biobank and INTERVAL studies, have
enabled an accurate description of the distribution and co-vari-
ation of platelet parameters in adult populations. We discuss
how genome-wide association studies have identified hundreds
of genetic associations with platelet count and mean platelet
volume, which in aggregate can explain large fractions of phe-
notypic variance, consistent with a complex genetic architecture
and polygenic inheritance. Finally, we describe the large genetic
diagnostic and discovery programmes, which, simultaneously to
genome-wide association studies, have expanded the repertoire
of genes and variants associated with extreme platelet pheno-
types. These have advanced our understanding of the pathogen-
esis of hereditary macrothrombocytopenia and support a future
clinical diagnostic strategy that utilises genotype alongside clini-
cal and laboratory phenotype data.
Keywords: platelets, macrothrombocytopenia, megakary-
opoiesis, genomics, polygenic.
Healthy adults produce and clear approximately 1 9 1011
platelets daily to maintain a stable platelet mass under steady
state conditions.1 Tight autoregulation of platelet mass is
important to prevent bleeding and thrombotic complications
from platelet counts that are too low or too high respec-
tively. Platelet production is primarily dependent on throm-
bopoietin (TPO), a glycoprotein produced by the liver,
kidneys and bone marrow.1 The uptake of TPO by high-
affinity TPO receptors (encoded by the MPL gene), drives
the proliferation and differentiation of the haematopoietic
stem cell (HSC) towards megakaryocytes (MKs) and sup-
ports the survival, proliferation and differentiation of MKs.1,2
Simultaneously, the TPO receptors of platelets act as a sink, cre-
ating a negative feedback loop regulating platelet production in
response to the level of free TPO.1 The expression of TPO
mRNA is itself regulated by the removal of platelets, which
become desialylated at the end of their circulatory lifespan.2
These desialylated senile platelets are bound by the Ashwell-
Morell (asialoglycoprotein) receptor on the hepatocyte surface,
which mediates platelet clearance from the circulation. Binding
to the Ashwell-Morell receptor also induces hepatocyte sig-
nalling through the JAK2-STAT3 pathway, leading to upregu-
lated TPO gene expression and secretion, thereby stimulating
new platelet production by MKs2
The variation in platelet count (PLT) and mean platelet
volume (MPV) between individuals is partly explained by
individual-specific environmental exposures, but also by
DNA sequence variations in the genes that regulate the plate-
let life cycle, including the fate decisions of HSCs. Disruption
to the tight regulation of platelet mass can result in throm-
bocytopenia (low platelet count) or thrombocytosis (high
platelet count). Macrothrombocytopenia, the frequent com-
bination of enlarged platelets with thrombocytopenia, has
many acquired causes, for example sepsis3 and immune
thrombocytopenia (ITP)4, however, in this review we will
focus on the pathogenesis of hereditary macrothrombocy-
topenia. We will first look at the technologies used for the
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clinical measurement of PLT and MPV. We will then con-
sider how large-scale population cohorts, such as UK Bio-
bank (UKB) and INTERVAL studies, can help delineate PLT
and MPV reference intervals. We will discuss the results of
recent genome-wide association studies (GWAS), showing
that the aggregate additive effect of genetic variation at hun-
dreds of independent loci can explain 19% and 27% of the
variation in normalised representations of PLT and MPV
respectively. These percentages are greater than those of most
other published genetic scores for quantitative traits, for
example those for weight and low-density lipoprotein con-
centration (both 8%).5,6 Height is a notable exception
(40%).7 We will illustrate how the hundreds of GWAS asso-
ciated genetic variants, many with small effects on PLT and
MPV, modify the risk of macrothrombocytopenia conferred
by variants, implicated in hereditary macrothrombocytopenia
disorders. Finally, we will focus on the rare hereditary
macrothrombocytopenia disorders and address some of the
clinical implications of an accurate molecular diagnosis.
The measurement of platelet count and volume
The standard clinical reference range for PLT in healthy
adults is 150–400 9 109/l.8 The historical reference method
for measuring PLT required manual counting of platelets
using phase contrast microscopy.8 This was superseded by an
immunological flow cytometry method that uses fluores-
cently tagged antibodies to the platelet-specific glycoproteins
GPIIb (CD41) and GPIIIa (CD61).9 This is recommended by
the International Council for Standardization in Haematol-
ogy (ICSH) and the International Society of Laboratory Hae-
matology (ISLH) for validation and standardisation of new
methods of cell counting.10 For clinical purposes, automated
haematology analysers measure PLT as part of a full blood
count (FBC). At present, the models of haematology analyser
most frequently registered in the UK are the Sysmex XN-ser-
ies, the Sysmex PocH-100i (Sysmex UK Ltd, Milton Keynes,
UK), and the Siemens Advia (Siemens, Erlangen, Germany)
(collectively 62%; National External Quality Assessment Ser-
vice (NEQAS) exercise December 2019, unpublished data).
Different analysers use different technologies to detect blood
cells and to distinguish platelets, which has important impli-
cations for the interpretation of PLT (and MPV) because the
method used can influence the accuracy and precision of
measurements, particularly in macrothrombocytopenic sam-
ples. The impedance method (or ‘Coulter principle’) relies
on the reduction in electrical conductivity caused by the dis-
placement of electrolytes as cells pass through a sensing aper-
ture or channel.8 The increase in impedance is proportional
to the volume of the traversing cell. Consequently, platelets
are distinguishable from larger blood cell types, but not from
similarly sized cells such as microcytic red blood cells (RBCs)
or fragments.8 If such cells/fragments are numerous, PLT can
be overestimated.8,11 Conversely, if unusually large platelets
are present, these cannot be reliably distinguished from
RBCs, and PLT can be underestimated.8 Modern analysers
often employ optical detection methods, in which the inten-
sities of diffracted light scattered by a cell at different angles
from an afferent light source are measured, sometimes
together with the intensity of light fluoresced by the cell.
These have improved ability to discriminate platelets, partic-
ularly in thrombocytopenic samples.8,12 Optical counters
classify cells according to the intensity of forward-scattered
(FSC), side-scattered (SSC) and side-fluorescence (SFL) light.
FSC measures cell volume, SSC provides information about
cell complexity, including granularity, and SFL quantifies the
RNA/DNA content of the cell. A division of the space of
possible measured intensities into regions (‘gates’) corre-
sponding to cell types is used to identify particular cell
groups, for example, platelets. More than one type of count-
ing instrument can be incorporated in the same analyser,
with an automated algorithm that detects interference, for
example from fragments in the impedance channel, or
detects an abnormal optical platelet distribution (e.g. in the
presence of white cell fragments in acute leukaemia or fol-
lowing chemotherapy).11–13 If one counting method is
deemed unreliable, the count from the alternative is
reported.11,13 Improvements to some optical counters allow
them to detect platelets using monoclonal CD61 antibodies
(e.g. Abbott Cell-Dyn Sapphire; Abbott Diagnostics, Santa
Clara, CA, USA)14 or cell-specific fluorescent dyes. The cur-
rent Sysmex XN-series analysers (Sysmex, Kobe, Japan) have
a dedicated channel for platelet analysis, PLT-F, which uses
oxazine, a platelet-specific fluorescent dye that binds nucleic
acids present in ribosomes and mitochondria.15–17 The PLT-
F method also incorporates an extended counting volume
and time, to reduce the variance in measurement of PLT.15
PLT-F correlates well with the ICSH/ISLH immunological
reference method, even in markedly thrombocytopenic sam-
ples, which is critical to guiding platelet transfusions.15,18
The volume of an individual platelet is measurable from
the magnitude of the change in impedance it induces or
from its optical scatter properties. The distribution of platelet
volumes within a blood sample is usually summarised by
two quantities: the mean average volume (i.e. MPV) and the
platelet distribution width (PDW), a measure of the variabil-
ity of platelet volume within the sample. MPV is derived
from the platelet crit (PCT; the percentage of blood volume
occupied by platelets, calculated from the sum of the mea-
sured volumes of platelets in a fixed volume of blood) and
PLT according to the formula MPV = PCT/PLT/100%.
Unlike for PLT, there is no agreed standard clinical reference
range for MPV, and this parameter is not currently included
in the UK NEQAS haematology exercises. A large epidemio-
logical study reported a reference range of 72–117 fL in
healthy European ancestry individuals.19 FBC samples were
analysed within 6 h of venepuncture on a Cell-Dyn 3700 SL
analyser (Abbott Diagnostics), which used impedance to
derive MPV.19,20 The comparability of MPV measurements
against a standard reference range is, however, affected by
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pre-analytical variability and differences between analyser
methodologies for platelet detection and for calculation of
PCT (and subsequent derivation of MPV).19,21,22 Sources of
pre-analytical variability include the choice of anticoagulant
and the extent to which platelets swell between venepuncture
and analysis; in EDTA, the majority of the increase in MPV
occurs in the first 6 h, with an overall increase in MPV of
134% at 24 h.21 The aggregate technical variation in MPV is
such that measurements may vary by up to 25% between
parallel analyses of the same sample by different instru-
ments.23 In macrothrombocytopenic samples, MPV derived
by impedance can be systematically underestimated because
the threshold used to discriminate platelets from other blood
cell types excludes large platelets. Most analysers will flag
samples for which the platelet size distribution is not demar-
cated and overlaps with that of other cell types. In such
cases, MPV may be omitted from the analyser report, or it
may be reported with a downward bias. Some instruments
adopt a liberal platelet detection window to avoid this prob-
lem. For example, the Siemens Advia 2120 analyser, which
uses optical detection, can detect platelets up to a volume of
60 fL and report an MPV up to 28 fL.23 However, a liberal
window risks upward bias in estimates of PLT and MPV, in
the presence of microcytic RBCs.23 A further practical
approach to detect large platelets from the output of auto-
mated haematology analysers is by manual inspection of the
platelet size distribution histogram. Macrothrombocytopenia
typically manifests as a right shift or skew in the distribution,
which is a helpful adjunct to considering the MPV and PDW
and interpretation of the blood film.
The reference method for assessment of platelet size is mor-
phological examination of platelets on a May-Gr€unwald-Giemsa
stained blood film by a trained cytologist.23 MPV cannot be
measured directly from a blood smear image, but mean platelet
diameter (MPD) and platelet diameter distribution width can
be calculated by software assisted image analysis.24 MPD corre-
lates with MPV, and offers the advantage of standardisation
between laboratories.25 Blood microscopy is already part of the
diagnostic pathway for thrombocytopenia in clinical diagnostic
laboratories, to detect platelet clumping, indicating pseu-
dothrombocytopenia, or to identify features such as leucocyte
inclusions and agranular platelets respectively to diagnose
MYH9-related disorders (MYH9-RD)26 and gray platelet syn-
drome (GPS).27,28 In principle, automated MPD measurement
could be included in this evaluation.
Variation in PLT and MPV in representative
populations
Our understanding of the distribution of platelet traits in the
general population has improved because of data from large
biomedical cohorts, specifically the measurement of partici-
pant FBCs at centralised laboratories using standardised pro-
tocols. These include the UKB, comprising 468 000
participants recruited through UK primary care registers,
who were aged between 40 and 69 years at baseline (2006–
2010),29 and the INTERVAL study of 45 000 British blood
donors aged 18 years or older at baseline (2012–2014).30,31.
FBC data for the participants in UKB study were generated
by Beckman Coulter LH 700 analysers (Beckman Coulter,
CA, USA), which determined PLT and MPV by impedance.32
FBC data for participants in the INTERVAL study were gen-
erated by Sysmex XN-1000 analysers, which determined PLT
optically by flow cytometry and derived MPV through PCT
by impedance.32 Analysers are not calibrated as strictly or
frequently for research as for clinical practice. Therefore, we
present here technically adjusted data to remove variation
explained by machine drift over time, the time of day of the
measurement and the time between venepuncture and analy-
sis.32 The median PLT is similar across the two cohorts
within both sex strata; however, PLT is approximately
30 9 109/l greater in females than males within both cohorts
(Mann-Whitney test P-value <1015) (Table 1; Fig 1). The
median MPV differs by less than 01 fL between sexes within
each cohort, indicating that, on average, women have a
greater circulating platelet mass than men. MPV is, in med-
ian, 21 fL higher in the INTERVAL cohort than the UKB
cohort, which is not explained by the different age distribu-
tions of participants in these studies. It is possible that differ-
ences in the measuring technology used by the two analyser
models are responsible, for example, the manufacturer-speci-
fic reagents used to prepare blood samples for analysis, which
may cause differential swelling of platelets.23,32 Irrespective of
the differences between these studies, both illustrate the vari-
ation of PLT and MPV within large UK populations. The
data highlight that PLT should perhaps be considered against
sex-stratified reference ranges, and MPV needs to be consid-
ered against reference ranges specific to the model of anal-
yser.
The large UKB collection illustrates the negative correla-
tion between PLT and MPV (Fig 2) with similar correlation
coefficients for males (r = 047) and females (r = 048).
Table 1. Statistical summaries of the distributions of platelet count
(PLT) and mean platelet volume (MPV) after adjustment of the
baseline measured values from the INTERVAL and UK Biobank
(UKB) cohorts for technical noise. The corresponding densities are











M 232 155–348 234 145–356
F 263 172–398 261 164–393
MPV (fL)
M 112 97–133 91 76–117
F 113 97–133 92 76–118
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Interestingly, variance weighted log-linear regression of PLT
on log(MPV), adjusting for sex and menopause and their
interactions with age, indicates an exceptionally good fit to
an inverse proportional dependence of mean PLT on MPV
in a maximal unrelated subset of European ancestry UKB
participants. The exponent of MPV is estimated as 0998
(with standard error 0003). This is consistent with biological
control of the total percentage of blood volume occupied by
platelets (i.e., PCT) around a common population average.
When all UKB participants with at least one of PLT or MPV
outside of their respective 95% reference intervals are consid-
ered, participants with both low PLT and high MPV are
substantially more prevalent than expected, if PLT and MPV
were distributed independently (0524% males, 0272%
females; expected frequency 00625%; Fisher’s exact test P-
value <22 9 1016). This suggests that on a population
scale, low PLT and high MPV together (macrothrombocy-
topenia) may be a composite trait representing one extreme
of a range.
Hereditary macrothrombocytopenia
The hereditary thrombocytopenia (HT) disorders are a
heterogeneous group of rare diseases with an estimated
Fig 1. Sex-stratified distributions of platelet parameters in the INTERVAL and UK Biobank (UKB) cohorts. The histograms show the distribu-
tions of baseline measurements of platelet count (PLT) and mean platelet volume on participants in the INTERVAL (n = 45 000) and UKB
(n = 468 000) cohorts, adjusted for technical artefacts. The horizontal dashed lines in each plot indicate the median, 2.5th and 97.5th percentiles
of the distributions. More than 995% of participants had a PLT between 50 and 500 9 109/l in both studies; PLT values >500 9 109/l are not
displayed.
Fig 2. Relationship between platelet count and mean platelet volume in males and females. The plots show the bivariate distribution of baseline
measurements of platelet count (PLT; X-axis) and mean platelet volume (MPV; Y-axis) in UKB, adjusted for technical artefact and stratified by
sex. The depth of the blue colouring corresponds to a kernel density estimate. PLT and MPV are negatively correlated in both males (r = 047)
and females (r = 048).
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combined incidence of 270 cases per million live births.33
Initial genetic sub-classification of HT was achieved by can-
didate gene studies of groups of patients with distinctive
common clinical or laboratory phenotypes, using Sanger
sequencing to resolve their genotype. In 2004, only nine
genes were known to carry aetiological mutations for HT dis-
orders (MYH9, GP1BA, GP1BB, FLI1, GATA1, RUNX1,
HOXA11, MPL and WAS).34 The development of high-
throughput sequencing (HTS) technology has enabled large-
scale testing using diagnostic gene panels for HT33,35–37 and
parallel research studies using whole exome sequencing
(WES)38 and whole genome sequencing (WGS)39 have sub-
stantially increased the repertoire of HT genes and the char-
acterisation of pathogenic variants within these genes. The
Scientific and Standardisation Committee on Genomics in
Thrombosis and Haemostasis of the International Society on
Thrombosis and Haemostasis (ISTH) have curated an evi-
dence-based catalogue of diagnostic-grade (TIER1) genes that
are causally implicated in bleeding, thrombotic and platelet
disorders (BPD),40 hereafter referred to as BPD genes. This
assignment is based on specific criteria, including the number
of reported independent pedigrees, the availability of func-
tional experimental data and the existence of animal models.
Presently, there are 40 TIER1 genes, in which mutations
cause HT disorders (Fig 3).40 In this review, we classify 29 of
these (73%) as hereditary macrothrombocytopenia (HMT)
genes (Fig 3; Table 2). Mutations in these HMT genes result
in platelets across a size spectrum from ‘normal/slightly
increased’ to ‘giant’, based on work by Noris et al.,24 which
we will discuss in more detail later. Rare variants in three
additional genes, PRKACG, TPM4 and TRPM7, co-segregate
with macrothrombocytopenia in small numbers of
pedigrees.41–43 Further evidence from genetically unrelated
patients is required before these can be re-classified as diag-
nostic-grade HMT genes.40 It is significant that macrothrom-
bocytopenia is observed in a large proportion of HT
disorders, consistent with an extreme manifestation of the
inverse population correlation between PLT and MPV
(Fig 2). However, since platelets are not enlarged in all HT
disorders, it is likely that some pathogenic mechanisms cause
subversion of the normal PLT-MPV relationship.
The discovery of many new HMT genes has, in part, fol-
lowed the inclusion of patients with BPDs in the thousands
of people with rare diseases whose DNA has been sequenced
as part of translational research programmes coordinated by
the National Institute for Health Research (NIHR) BioRe-
source. By July 2020, 13 037 patients with rare diseases and
their close relatives had undergone DNA analysis by WGS as
part of NIHR programmes; 1169 of these patients suffered
from an unexplained BPD,39 adding to an earlier cohort of
patients with BPD who underwent WES.38 Additionally, the
ThromboGenomics (TG) HTS diagnostic panel test, devel-
oped to screen bleeding, platelet and thrombotic genes
known to carry aetiological mutations, has been applied to
more than 2,500 patients with a BPD.37 Collectively, these
BPD cases represent the largest cohort with detailed pheno-
typing and genotype sequencing data in the world. A multi-
disciplinary team (MDT) identified a causal variant in a
HMT gene in 480 cases (Fig 4, Table 2). The four most fre-
quently implicated genes were MYH9, ACTN1, ANKRD26
and TUBB1, which together accounted for 48% of the geneti-
cally explained cases of HMT. Many HMT genes, including
genes that represent aetiological discoveries from the past
6 years (ACTB,44 CDC42,45 GNE,46,47 MECOM,48,49 and
Fig 3. Genes associated with hereditary thrombocytopenia disorders. The genes names are shown beneath a schematic representation of the stages
of differentiation from haematopoietic stem cells (HSC) to proplatelet forming megakaryocytes (MK). The genes in which rare pathogenic vari-
ants cause hereditary thrombocytopenia (HT; grey) and hereditary macrothrombocytopenia (HMT; bold) disorders are indicated, grouped into
categories by pathogenesis. Adapted with permission from Lentaigne et al.78
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MPIG6B50,51), explained only a handful of cases (Fig 4). Of
the 480 cases, 95% of the reported variants were single
nucleotide variants or small insertion/deletions in HMT
genes. In 23 cases (5%), a copy number variant (CNV) was
identified. Deletions were reported in ABCG5 (1), DIAPH1
(1), ETV6 (1), FLI1 (5), GP1BB (3), GP9 (1), ITGB3 (1) and
RUNX1 (10). In one case, an inversion in RUNX1, explained
the patient’s macrothrombocytopenia. CNV calling by HTS
has improved significantly, specifically for deletions; however,
identification of duplications and more complex structural
rearrangements remains challenging (e.g. the F8 inversion is
not detectable by HTS). Nonetheless, analysis of structural
variants is essential to perform an exhaustive molecular
diagnostic, especially where a clear phenotype is present and
no causative variant has been identified [or only one variant
has been identified in a suspected autosomal recessive (AR)
disorder].37,39,52 The relative frequencies of HMT disorders
in the case collection are representative of those expected
amongst presentations at a tertiary referral haemostasis clinic,
with one qualification. Patients carrying variants in NBEAL2,
the aetiological gene for GPS, are over-represented in this
study because of the proactive efforts by NIHR researchers to
collate an international cohort of patients to investigate the
specific pathology of this disease.28 No causative variants
were identified in 41% of patients with macrothrombocy-
topenia referred to TG,37 a proportion similar to those of
Fig 4. Genes containing rare causative variants in 480 cases undergoing next generation sequencing for diagnosis of hereditary macrothrombocy-
topenia (HMT). Genotype data for cases with unexplained HMT were measured using the ThromboGenomics high-throughput sequencing gene
panel test (TG) or by whole genome (WGS) or exome (WES) sequence analysis of patients enrolled into the bleeding, thrombotic and platelet
disorders (BPD) sub-study of the NIHR-BioResource rare diseases. Each bar represents an HMT disorder grouped by HMT gene, ordered and
coloured by category of pathogenesis. In nine cases, variants were reported in two HMT genes. Gene names in bold are linked to disorders with
an autosomal dominant mode of inheritance (MoI), and the remainder either autosomal recessive or X-linked MoI. An asterisk above the disor-
der/gene name depicts HMT genes discovered after 2015. Y-axes on the left and right give the absolute number and proportion of patients respec-
tively. BDPLT16, platelet-type bleeding disorder 16; BSS, Bernard-Soulier syndrome; MMT, mild macrothrombocytopenia; PTVWD, platelet type
von Willebrand disease; STSL, sitosterolemia with macrothrombocytopenia.
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other research programmes using HTS.33,36 This illustrates
the extent to which the genetic architecture of HMT remains
incompletely understood. Indeed, there are two phenotypi-
cally distinct HMT disorders, White Platelet Syndrome53,54
and Medich Platelet Syndrome,55,56 for which no causal
genes have yet been identified. New genes causing Mendelian
forms of HMT are likely to be identified by ongoing research
of large, rare disease cohorts. It is also possible that some
HMT cases can be explained completely or partially by the
non-Mendelian inheritance of an extreme polygenic load of
low PLT predisposing alleles. Because of the potential diag-
nostic impact, in the following sections we will first address
the recent advances in detecting common genetic variants
regulating PLT and MPV, and then focus on the pathogene-
sis of the HMT disorders. Finally, we will cover the clinical
implications of correctly identifying the cause of
macrothrombocytopenia.
The genetic architecture of PLT and MPV in
healthy populations
Quantitative blood cell traits have heritable components of
variation.57,58 Common genetic variation is estimated to gen-
erate 5–30% of the total variability in FBC traits measured in
the European ancestry population.32 Over the past decade,
increasingly large GWAS analyses of FBC phenotypes have
been performed to identify genetic variants perturbing hae-
matopoiesis or blood cell clearance mechanisms.32,59–62 The
largest and most recent studies are by the Blood Cell Consor-
tium (BCX), synthesising evidence from the UKB, INTER-
VAL and several other cohorts, in European ancestry and
trans-ethnic meta-analyses.63,64 Typically, each participant
contributing to these studies had genotypes measured at a
few hundred thousand variants, most of which were com-
mon, spread more or less uniformly across the genome. Sub-
sequently, the genotypes for millions of variants not
measured in the study participants were imputed computa-
tionally. Unmeasured genotypes can be imputed by matching
measured genotypes to the haplotype structure observed in
the panels of thousands of independent individuals with
publicly available genotypes measured by WGS.65–67 The
BCX European ancestry GWAS had a sample size
(n = 563 085) quadruple that of the largest preceding study
and tested more than 41 million single nucleotide polymor-
phisms for association with each of 29 FBC phenotypes,
including PLT and MPV.32,63 The analysis identified 16 900
variant-trait association signals across the 29 FBC pheno-
types.63 These were assigned to at least 7,122 genomic tags,
each either a distinct causal variant itself or strongly corre-
lated (i.e., in strong linkage disequilibrium) to a distinct cau-
sal variant. Of these tags, 1,227 were associated with PLT
and/or MPV. Of these, 117 (96%) were low frequency vari-
ants (minor allele frequency, (MAF) 1–5%) and 77 (63%)
were rare variants63 (MAF < 1%) (Fig 5A). In keeping with
evolutionary theory, there is an inverse relationship between
MAF and the maximum absolute effect size of a variant tol-
erated by natural selection (Fig 5A). Only variants with small
effect sizes (<04 standard deviations (SD) per allele) have
been able to attain a MAF of > 1%.63 Conversely, rare vari-
ants, which on average have arisen more recently in evolu-
tion, exhibited absolute effect sizes as large as 086 SD per
allele.63 Interestingly, amongst the variants with genome-wide
significant associations with one of PLT or MPV, there is a
tendency for alleles associated with greater MPV to be associ-
ated with lower PLT and vice-versa (Fig 5B).63 The annota-
tion of variants by their computationally predicted
transcriptional consequences, recapitulated observations from
earlier GWAS that approximately 90% of variants associated
with FBC phenotypes are located outside exons, in the non-
coding regions of the genome and are, therefore, likely to
exert a phenotypic effect by altering gene regulation.32,63,68–71
Indeed, FBC associated variants were significantly enriched in
open chromatin regions [(measured by assay for transposase-
accessible chromatin using sequencing (ATAC-seq)] of 18
human haematopoietic progenitor cell types.63,72 Variants
associated with platelet phenotypes specifically were enriched
in the open chromatin regions of MKs and in certain other
myeloid precursor cell types.63 However, platelet associations
with coding and non-coding variants in, or physically adja-
cent to, BPD genes were enriched only in MKs. This suggests
that the regulators of genes implicated in BPD act more
specifically in MKs.63 Common and low frequency variants
associated with PLT or MPV are overwhelmingly (85%) inter-
genic or intronic.63 By comparison, 60% of rare variants asso-
ciated with PLT or MPV fall into these categories63 and rare
variants are much more likely than common variants to alter
the amino acid sequence of a protein. There is a statistically
significant overlap of 16 genes between the set of 29 HMT
genes, and the set of 1185 genes in loci containing genetic
associations with PLT or MPV (Fig 6). This illustrates that
the same biological mechanism can be disturbed by multiple
variants with effect sizes on a continuum. Variants with large
effects on MPV or PLT are almost always rare and are more
likely than variants with small effects to alter the structure of
a protein rather than just disrupt the level of gene expression;
variants with extreme effect sizes can disrupt biological func-
tion to such a degree that they cause disease. Consequently,
genes with no known functions in MK or platelet biology, but
in loci containing variants with large effects on PLT or MPV
(e.g. CKAP2L, PLEK and TNFRSF13B),63 are credible candi-
dates to explain molecularly undiagnosed cases of HMT.
The polygenic risk of macrothrombocytopenia
Genome-wide association studies, such as the BCX studies,
are now so large they can provide precise estimates of the
effects on quantitative traits of single allele copies of rare
variants known to cause AR disorders in homozygosity. Such
studies have shown, in particular, that the population distri-
butions of PLT and MPV in heterozygous carriers of alleles
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known to cause recessive BPDs can differ dramatically from
the corresponding distributions in non-carriers.32,63 Variation
in PLT and MPV between individuals, due to background
measurement and environmental and genetic factors, may
explain why it has not been possible previously to demon-
strate co-segregation of heterozygote effects within individual
pedigrees, despite their relatively large population effect sizes.
One example of this phenomenon is the THPO gene, which
encodes TPO. AR inheritance of two loss-of-function (LoF)
variants in THPO causes severe thrombocytopenia and,
sometimes, tri-lineage bone marrow failure,73 whereas
monoallelic LoF variants in THPO cause a mild
macrothrombocytopenia only.74,75 Another example from the
BCX GWAS, relates to the GP9 variant rs5030764, which
changes asparagine to serine at residue 61 of glycoprotein IX
(GPIX), one of the proteins of the GPIb/IX/V platelet recep-
tor for von Willebrand factor (VWF). In homozygosity or in
compound heterozygosity with another pathogenic allele, the
minor allele of rs5030764 causes Bernard-Soulier syndrome
(BSS).37 However, the allele also affects heterozygote carriers,
for whom thrombocytopenia is three times more prevalent
than usual in the UKB baseline FBC data.63 The observation
that heterozygote effects can be strong motivates the ques-
tion, what is the consequence of inheriting AR alleles in
heterozygosity in two different genes, and could this lead to
a BPD phenotype, such as HMT? More generally, it can be
hypothesised that some molecularly unexplained cases of
HMT are due to the aggregate genome-wide polygenic effect
of multiple alleles, each of which simultaneously predisposes
the carrier to a lower PLT and greater MPV, perhaps com-
pounded by pathogenic, or likely pathogenic, AR variants or
by environmental exposures. This hypothesis is supported by
recent studies of polygenic scores (PGS) for FBC traits.63 A
PGS is a numerical predictor of a quantitative trait or of a
disease liability, constructed as a weighted sum of allele
counts from numerous variants associated with the outcome
of interest. The weights are usually chosen to be proportional
to the marginal or joint effect of the variant on the trait of
interest, estimated by regression. The effect of a one SD
decrease in the PGS for PLT, developed by Vuckovic et al.,
was comparable to the effect of a pathogenic rare variant in
heterozygosity.63 One way of presenting differences in
Fig 5. Phenotypic effect size of variants associated with platelet traits in the UKB genome-wide association studies (GWAS). (A) The scatterplots
show the minor allele frequencies (MAF) of variants associated with platelet count (PLT) (left panel) and mean platelet volume (MPV) (right
panel) in the UKB study on the X-axis. The effect size of each variant is shown on the Y-axis, expressed as the per allele effect of the variant on
the mean of each parameter distribution expressed in standard deviations (SDs) of the respective distribution. (B) The inverse relationship
between effect sizes for PLT and MPV. The colour gradient of the dots indicates the logit transformed MAF. Effect sizes are expressed as
described above.
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polygenic risk is to make comparisons between groups with
a high or low PGS, defined by quantiles of the population
distribution. The distributions of PLT in the subsets of UKB
participants forming the lowest and greatest deciles of the
PGS for PLT constructed by Vuckovic et al. are shifted left
and right respectively, relative to the distribution of PLT in
all participants (Fig 7A). Combined inheritance of a
heterozygous pathogenic variant in GP9 and a low PGS may,
by an additive effect on PLT, manifest as macrothrombocy-
topenia. Conversely, inheritance of a high PGS may mitigate
the increase in disease risk due to the pathogenic allele,
resulting in a PLT within the normal range (Fig 7B). Risk
modifying environmental and genetic variation, including
that captured by PGS, can make pathogenicity assignment
challenging. This is illustrated by the variant rs41303899 in
TUBB1 (Fig 7C), the minor allele of which is strongly associ-
ated with lower PLT (on average 33 9 109/l), and which
when inherited in addition to a low PGS can have a joint
effect on PLT sufficient to result in macrothrombocytope-
nia.63 However, many carriers, in particular those with a high
PGS, have a PLT within the normal range,63 suggesting that
this variant would be better classified as risk-associated rather
than pathogenic. These examples illustrate how polygenic
variation can modify the penetrance of rare variants with
large effect sizes in the pathogenesis of HMT. In the future,
it may be possible to diagnose a proportion of molecularly
uncharacterised HMT cases, as caused by a very extreme
PGS, perhaps in combination with a heterozygous pathogenic
rare variant, although it is likely these patients will represent
a small fraction of all cases.
The hereditary macrothrombocytopenia
disorders
The characterisation of causal genetic variants in HMT has
improved our understanding of the normal regulation of plate-
let production. Considering all HMT disorders, there are
examples that result in dysfunction of several major steps in
megakaryopoiesis and platelet formation, including MK differ-
entiation, MK maturation and proplatelet formation (Fig 3).
The clinical and genetic characterisations of HT and HMT dis-
orders have recently been reviewed.76–80 We will primarily
focus on the pathogenesis of a subgroup of HMT disorders
distinguishable by the presence of ‘very large’ platelets, in
which there is preservation and exaggeration of the inverse
relationship between PLT and MPV that is observed in healthy
populations. In a diagnostic classification proposed by Noris
et al., based on a large study of 376 patients with 19 different
Fig 6. Overlap between genes identified by genome-wide association studies (GWAS) and genes implicated in hereditary macrothrombocytopenia
(HMT) disorders. (A) Chromosome ideogram showing the positions of the 1185 gene loci with variants identified by GWAS as being associated
with platelet count or mean platelet volume (blue bars) and the 29 genes implicated in HMT disorders (red bars). The 16 HMT genes falling
within 5 kb of a GWAS locus are marked with an orange dot. The Y chromosome is not presented, as this was not included in the GWAS analy-
sis. ABCG5 and ABCG8 lie in close proximity at 2p21 and are represented by only one red bar. (B) Diagram displaying the overlap between 16
genes in GWAS loci, in which rare variants cause HMT.
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HT disorders, ‘large’ and ‘giant’ platelet disorders were those
in which the MPD was greater than 32 lM [with a platelet
diameter large cell ratio, (PDLCR) >20%] and 40 lM (with
PDLCR >50%) respectively24 (Fig 8; Table 2). Strikingly, the
11 genes, in which rare pathogenic variants lead to the HMT
disorders in this subgroup24 all have functional roles in pro-
platelet formation. Nine genes have critical roles in cytoskele-
ton regulation (ACTN1, FLNA, MYH9 and TUBB1) and
expression of surface membrane glycoproteins at the later
stages of MK differentiation (GP1BA, GP1BB, GP9 encoding
proteins GPIba, GPIbb, GPIX; ITGA2B, ITGB3 encoding inte-
grin aIIb and b3)79,80 (Figs 3 and 8; Table 2). The remaining
two genes, GFI1B and NBEAL2, also have functional roles in
cytoskeletal reorganisation.81,82 In contrast, five genes associ-
ated with platelets that were ‘normal/slightly increased’ in size
(ANKRD26, FLI1, GATA1, HOXA11 and RUNX1)24 have roles
in transcription regulation in early megakaryopoiesis79,80
(Figs 3 and 8).
Fig 8. Proposed classification of hereditary thrombocytopenias (HTs) using platelet size parameters. In this classification proposed by Noris
et al.,24 19 HTs associated with variants in 20 genes are sub-classified according to mean platelet diameter (MPD) and platelet diameter large and
small cell ratio (PDLCR and PDSCR respectively; percentage of platelets above the 97.5th percentile and below the 2.5th percentile of the platelet
diameter distribution in controls). HTs are listed by associated gene (the three HTs associated with GP1BA are also indicated in brackets). The
platelet illustrations for each category are to a relative scale. BSS, Bernard-Soulier syndrome; MMT, mild macrothrombocytopenia; PTVWD, pla-
telet type von Willebrand disease.
Fig 7. Representation of the interplay between polygenic trait scores (PGS) and the effect of monogenic variants casual of hereditary
macrothrombocytopenia (HMT) disorders. (A) Platelet count (PLT) distribution for all participants in the UKB cohort (black line) and for those
participants in the top 10% (green line) and bottom 10% (purple line) of the PGS for PLT respectively. (B) PLT distribution (black-line) for all
UKB participants and UKB participants who are carriers of the GP9 variant rs5030764 (dotted black line). Vertical lines in green and purple
respectively represent the rs5030764 carriers with top 10% and bottom 10% PGS values. The black arrows indicate the PLT for three patients with
Bernard-Soulier syndrome caused by rs5030764 in homozygosity. (C) Similar plots showing UKB participants who are carriers for the TUBB1
variant rs41303899. The black vertical line in the three panels marks a PLT of 150 9 109/l, the lower limit of the normal range.
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The cytoskeleton is composed of tubulin microtubules,
actin filaments and intermediate filaments constructed from
different subunit proteins, which in combination provide
shape and organisation to the MK and enable the cytoplasm
to be packaged into multiple long protrusions called pro-
platelets.83 Current models of platelet production suggest
that platelets develop at the proplatelet tips and receive their
granule contents through active cytoskeleton-mediated trans-
port. Subsequent fission events enable the release of platelets
into the circulation.84 Rare variants in critical genes that dis-
rupt cytoskeletal rearrangement and proplatelet formation
appear to impair the release of mature platelets, and instead
preferentially release immature, abnormally large platelets,
resulting in macrothrombocytopenia.85,86
MYH9 is the most frequently implicated gene in patients
with HMT, and underlies five historically recognised clinical
disorders, May-Hegglin anomaly, Epstein syndrome, Fechtner
syndrome, Sebastian syndrome and Alport syndrome with
macrothrombocytopenia.26,87,88 Patients with these autosomal
dominant (AD) disorders had macrothrombocytopenia, giant
platelets, leucocyte inclusions and a combination of addi-
tional clinical features (Table 2). Following the discovery of
underlying pathogenic variants in MYH9, they became collec-
tively termed the MYH9-related disorders (MYH9-RD) in
which different clinical features are likely to represent vari-
able expressivity.89,90 MYH9 encodes the heavy chain of non-
muscle myosin IIA, which belongs to a family of cytoskeletal
proteins that slide along actin filaments and generate
mechanical forces to enable proplatelet formation, fragmenta-
tion and platelet release.76 The association between cytoskele-
tal genes and HMT is further illustrated by TUBB1, ACTN1
and FLNA, in which rare monoallelic variants lead to a mild-
moderate reduction in PLT (typically 50–100 9 109/l in
FLNA-related macrothrombocytopenia and >100 9 109/l in
the others), large platelets and usually mild or absent bleed-
ing symptoms.80 We have already touched on TUBB1 to
illustrate the penetrance modifying effect of polygenic varia-
tion. TUBB1 encodes b1-tubulin, the main tubulin isoform
in MKs, critical to proplatelet extension, release of platelets
and determination of platelet size.91,92 ACTN1 encodes a1-
actinin, which acts to crosslink actin filaments93 and FLNA
encodes filamin A, which binds the intracytoplasmic domain
of GPIba to the actin filament network; these proteins act to
stabilise the actin cytoskeleton.80,94,95 GFI1B encodes a zinc
finger protein, which is a transcriptional regulator necessary
for development and differentiation of the MK and erythroid
lineages.81 Dominant negative mutations in GFI1B cause
macrothrombocytopenia and a variable bleeding diathesis
caused by a deficiency of platelet alpha (a)-granules and
abnormal platelet activation responses including cytoskeletal
dysregulation.81,96,97 NBEAL2 encodes a scaffolding protein,
crucial to a-granule biogenesis; biallelic variants lead to
GPS27,28 and it is proposed that macrothrombocytopenia
results from defects in the Rac1/Cdc42 pathway and subse-
quent dysfunctional cytoskeleton reorganisation.82
Paradoxically, variants in other genes with critical roles in
cytoskeletal regulation, such as WAS and ARPC1B, lead to
microthrombocytopenia, possibly though an alternative effect
on proplatelet formation or through increased rates of
peripheral platelet clearance, resulting in small platelets.98
Genes involved in extracellular signalling to the cytoskele-
ton via membrane-bound receptors are also crucial to the reg-
ulation of platelet formation and release.79 Biallelic LoF
variants in GP1BA, GP1BB and GP9 disrupt proplatelet for-
mation by reducing or altering VWF binding to the GPIb/IX/
V receptor and cause BSS, an AR disorder associated with sev-
ere mucocutaneous bleeding.99 Platelets in BSS are historically
described as ‘giant’, because, as in the MYH9-RDs, some pla-
telets appear larger than RBCs on microscopy (Fig 8).24
Monoallelic LoF variants in GP1BA or GP1BB result in a less
severe phenotype, termed mild macrothrombocytopenia.100–
102 Deletion of a region of the long arm of chromosome 22
(22q11.2), which includes GP1BB, occurs in approximately
1:2000–6000 live births and leads to the disorders DiGeorge
syndrome or Velocardiofacial syndrome.103 Affected patients
have macrothrombocytopenia, moderate-severe bleeding and
a broad range of other clinical features103 (Table 2). Gain-of-
function (GoF) variants in GP1BA or VWF, which cause plate-
let-type von Willebrand disease104–107 and Type 2B von Wille-
brand disease108,109 respectively, result in enhanced receptor-
ligand interaction and disrupted megakaryopoiesis. Platelets
in these conditions are normal or only slightly increased in
size24 and likely to be related to increased platelet clearance;
patients do not have any additional clinical features.
Biallelic LoF variants in either ITGA2B or ITGB3 cause
Glanzmann thrombasthenia, in which patients typically have
severe mucocutaneous bleeding due to absent surface expres-
sion of the integrin aIIbb3, resulting in defective aggregation
and outside-in platelet signalling, but PLT is typically within
the normal range.110 ITGA2B and ITGB3 may also harbour
rare monoallelic GoF missense variants, in which the main
manifestation is macrothrombocytopenia, sometimes causing
bleeding.110–113 These GoF variants are thought to lead to
constitutive activation of aIIbb3, which impacts actin
cytoskeleton reorganisation and results in defective pro-
platelet and subsequent platelet formation.114,115
Three more recently discovered HMT genes further sup-
port the importance of cytoskeletal dysfunction in the HMT
phenotype: DIAPH1, ACTB and CDC42. Patients with rare
causative variants in DIAPH1 have moderate macrothrombo-
cytopenia without bleeding complications, but severe sen-
sorineural deafness and often mild neutropenia.116,117
DIAPH1 encodes a member of the formin protein family,
which controls GTPase dependent assembly of actin and
microtubule regulation during cytoskeletal remodelling.116
The variants underlying DIAPH1-associated macrothrombo-
cytopenia lead to constitutive activation of the DIAPH1 pro-
tein, which disrupts cytoskeletal and microtubule function
and impairs proplatelet formation.116 Rare variants in ACTB
were only very recently discovered as causative of HMT,
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resulting in platelets with an MPD in the ‘large platelet’ dis-
order range.24,44 ACTB encodes b-cytoplasmic actin and
pathogenic variants in the 3’ region disrupts microtubule
organisation in MKs.44 Finally, CDC42, which encodes a
member of the Rho family of small GTPases, has a major
role in cytoskeletal remodelling and intracellular signalling.45
A subgroup of monoallelic missense variants in CDC42 lead
to macrothrombocytopenia and a variety of developmental
and multisystem features, but no apparent haemostatic
abnormality45 (Table 2).
There are a number of additional HMT genes that are
understood to play a role in late megakaryopoiesis but with
incompletely defined pathways. For example, monoallelic
variants in SRC and SLFN14 disrupt MK maturation and
result in reduced proplatelet formation, causing macrothrom-
bocytopenia with variable bleeding phenotypes.80,118,119 In
the case of SRC variants, there are myriad other clinical fea-
tures including bone marrow fibrosis118 (Table 2).112 The
recent discoveries of variants in MPIG6B and GNE, as causes
of AR HMT disorders, provide new insights into the patho-
genesis of proplatelet formation. MPIG6B is located in the
major histocompatibility complex locus and encodes a trans-
membrane receptor of the immunoglobulin superfamily.50,51
MPIG6B is expressed on the surface of MKs and platelets
and when non-functional, leads to impaired proplatelet for-
mation.51 GNE encodes an enzyme (glucosamine (UDP-N-
acetyl)-2-epimerase/N-acetylmannosamine kinase), involved
in the sialic acid biosynthesis pathway that is expressed in all
haematopoietic cells.46,47 Biallelic LoF variants in GNE reduce
sialic acid biosynthesis, impairing platelet formation and
increasing platelet clearance.46,47
Clinical implications
It is critical to distinguish between acquired and hereditary
macrothrombocytopenia, to enable appropriate management.
This includes the avoidance of treatments that are not indi-
cated and potentially harmful in patients with HMT disor-
ders. The most common example is the use of
immunosuppressants following a misdiagnosis of ITP.34
Additionally, patients have been inappropriately treated with
5-azacytadine for myelodysplastic syndrome, following the
observation of dysmegakaryopoiesis on bone marrow biopsy,
and prior to receiving a genetic diagnosis of AD thrombocy-
topenia 2 due to ANKRD26 mutations.120
Accurate molecular diagnosis in HMT is crucial to provide
patients and clinicians with an accurate diagnosis and prog-
nosis. There is an association between some HMT disorders
and the development of malignancy, for example those
caused by variants in ANKRD26,121 ETV6,122 and RUNX1.123
Patients with these disorders can present with only mild
macrothrombocytopenia, and absent or mild bleeding symp-
toms, therefore, a high index of clinical suspicion is required
to resolve the diagnosis. Of 29 patients with a working diag-
nosis of ‘ITP refractory to treatment’, referred to TG, seven
were diagnosed with HMT disorders, including ANKRD26
and ETV6 mutations.37 Monitoring of patients with a ‘pre-
malignant’ genetic profile for the emergence of detrimental
somatic mutations also has potential to improve survival.124
Many HMT genes are expressed in other blood cells and
tissues, explaining the additional clinical features displayed in
a number of HMT disorders, which may have a greater
impact on a patient’s health than bleeding complications
(Table 2). For example, approximately 30% of patients with
MYH9-RDs are at risk of end stage renal failure (ESRF) sec-
ondary to glomerulonephritis, 60% acquire a sensorineural
hearing defect and 16% develop pre-senile cataracts.125 There
is genotype–phenotype correlation between the molecular
defect and these disease manifestations; variants modifying
arginine at position 702 of the protein, located in the head
of myosin IIA, lead to glomerulonephritis, whereas variants
affecting the non-helical portion of the tail almost never
associate with this phenotype.125 Early pharmacological inter-
vention with angiotensin-converting enzyme inhibitors and/
or angiotensin receptor blockers can prevent deterioration to
ESRF.125 Therefore, a precise molecular diagnosis assists in
best management of this condition.
Treatment of HMT disorders currently focuses on prophy-
laxis prior to high-risk procedures and treatment of acute
bleeding. For example, for patients with BSS, the mainstay of
prophylactic treatments are tranexamic acid and transfusions
of HLA class I matched platelets.126 There is little evidence for
the effectiveness of desmopressin and recombinant human
activated factor VII for bleeding, which is licensed for patients
with Glanzmann thrombasthenia but not BSS.126 Patients
with both MYH9-RDs and macrothrombocytopenia with sen-
sorineural hearing loss due to DIAPH1 mutations have
responded to treatment with the TPO receptor agonist (TPO-
RA) eltrombopag.117,127 In a recent prospective phase II clini-
cal trial, 24 patients with five different HT disorders were
treated with eltrombopag.128 The average increase in PLT
from baseline was 645 9 109/l, with more than 90% of the
patients responding to treatment, and patients with MYH9-
RD and BSS achieving the greatest response. These results are
encouraging for the use of TPO-RAs to prepare patients with
HMT disorders for elective procedures, without the need for
platelet transfusion, although further clinical data is
needed.128 Currently, HSC transplantation is the only curative
treatment for severe HMT disorders, including BSS and
amegakaryocytic thrombocytopenia with radioulnar synosto-
sis.125 As our knowledge of the molecular pathways regulating
megakaryopoiesis and platelet formation advances, we pave
the way for identification of new therapeutic targets. It is also
conceivable that gene therapy may become an option in the
future for HMT disorders associated with severe pathologies.
The effect of polygenic variation on PLT has aetiological
relevance for HMT and might have diagnostic implications.
In the previous TUBB1 example, we demonstrated that a
person who inherits a rare monogenic variant in an HMT
gene may also, by chance, inherit a high PGS for PLT,
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resulting in aggregate to a typical risk of macrothrombocy-
topenia, i.e., the polygenic variation masks or compensates
for the rare monogenic variant. This phenomenon is unlikely
to have harmful clinical consequences in the case of TUBB1
because, other than mild macrothrombocytopenia, rare vari-
ants have no known phenotypic consequences. However, if
we consider genes in which rare pathogenic variants cause
thrombocytopenia and also confer a risk of malignancy, in
theory, an extreme polygenic compensation that makes
thrombocytopenia less likely to be detected and investigated
could potentially have clinical implications. In addition, a
low PGS for PLT combined with an environmental trigger,
such as a viral infection or pregnancy, could have clinical
consequences, for example, by increasing the likelihood of
PLT dropping to below safe thresholds for invasive proce-
dures. On the other hand, a high PGS for PLT may lead to
an individual being extensively investigated for a reactive or
genetic cause of thrombocytosis. Therefore, in the clinical
setting, understanding an individual’s PGS could potentially
influence the management of patients presenting with both
low and high PLT.
Conclusion
The majority of HT cases are accompanied by enlarged plate-
lets, that is, macrothrombocytopenia. In some cases, platelets
are only subtly increased in size, including in HMT disorders
caused by variants in transcription factor genes (e.g.
ANKRD26). More frequently, macrothrombocytopenia is
pronounced and a common causative mechanism is dysregu-
lation of proplatelet formation. These HMT disorders lie at
one extreme of the PLT and MPV variation, which is nega-
tively correlated at a population level. There are technical
challenges in measuring PLT and MPV, particularly relevant
in macrothrombocytopenic blood samples. However, accu-
rate and precise measurements are fundamental to the work-
up of thrombocytopenia, to identify the underlying pathol-
ogy. This is to help to distinguish between acquired and
hereditary causes and because platelet volume/size measure-
ments, which provide a well-defined clinical phenotype
alongside other haematological, morphological and organ
system abnormalities, enable the MDT to assign pathogenic-
ity to variants identified by HTS-based testing. On the TG
platform, the diagnostic yield for patients with macrothrom-
bocytopenia was 59%, compared to 40% for patients with
thrombocytopenia (where either MPV was normal or a value
not provided) and 37% across all patients with a BPD.37
Huge advances in the availability and diagnostic capacity
of HTS platforms, such as TG,35,37 the UK Genotyping and
Phenotyping of Platelets study,33 and the Spanish HTS plat-
form for the diagnosis of hereditary platelet disorders,36
make early incorporation of genetic testing appropriate and
feasible. Where targeted HTS panels cannot identify a causa-
tive gene, enrolment into a WGS project, such as the follow
up to the 100 000 Genomes Project, is important for
identification of new causative genes to expand our knowl-
edge of the pathogenesis of HMT disorders.39 In England,
these new NHS-based diagnostic services are being made
available through a network of seven NHS Genomic Labora-
tory Hubs. The contribution of the polygenic predisposition
to macrothrombocytopenia may explain a proportion of
patients without a molecular diagnosis. However, further
research is needed in patient cohorts in order to confirm the
effects detected in healthy populations.
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